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1  |  INTRODUC TION
Oral lichen planus (OLP) is a common chronic inflammatory disease 
of the oral mucosa, with a global prevalence of 1.01% (Gonzalez- 
Moles et al., 2020). The pathogenesis of OLP is believed to involve 
a dysregulation of the immune system, (Jontell and Holmstrup, 
2015; Zucoloto et al., 2019) including presentation of an unknown 
antigen, T lymphocyte activation and migration, production of pro- 
inflammatory cytokines and chemokines resulting in sub- epithelial 
inflammatory infiltrate, keratinocytes damage and disruption of 
epithelial homeostasis. (Ke et al., 2017; Lu et al., 2015; Marshall 
et al., 2017) Available evidence suggests that CXCL10 and IFN- γ 
are key players in OLP- associated inflammation, (Tao et al., 2008) 
and previous in vitro studies showed that multi- strain probiotics 
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Abstract
Objective: To preliminary evaluate the clinical effects of probiotics in individuals with 
symptomatic oral lichen planus and the possible mechanisms of action.
Subjects and Methods: A group of 30 individuals with symptomatic oral lichen planus 
were recruited in a randomised double- blind parallel group controlled (1:1) proof- of- 
concept pilot trial of probiotic VSL#3 vs placebo. Efficacy outcomes included changes 
in pain numeric rating scale, oral disease severity score and the chronic oral mucosal 
disease questionnaire. Adverse effects, home diary and withdrawals were assessed as 
feasibility outcomes. Mechanistic outcomes included changes in salivary and serum 
levels of CXCL10 and IFN- γ and in oral microbial composition.
Results: The probiotic VSL#3 was safe and well tolerated. We observed no statisti-
cally significant change in pain, disease activity, quality of life, serum/salivary CXCL10 
or oral microbial composition with respect to placebo. Salivary IFN- γ levels demon-
strate a trend for a reduced level in the active group (p = 0.082) after 30 days of 
probiotic consumption.
Conclusions: The present proof- of- concept study provides some weak not convincing 
indication of biological and clinical effects of probiotic VSL#3 in individuals with pain-
ful oral lichen planus. Further research in this field is needed, with the current study 
providing useful information to the design of future clinical trials.
K E Y W O R D S
oral lichen planus, probiotic, the clinical and biological effects of the use of probiotic in 
patients with oral lichen planus, VSL#3
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are capable of suppressing LPS- induced chemokines, including 
CXCL10, through the blockade in the phosphorylation of the tran-
scription factor STAT1. (Mariman et al., 2014) Clinically the disease 
presents with reticular hyperkeratotic changes of the oral mucosa, 
with more than 50% of the affected individuals also developing 
long- standing erosion and ulceration leading to reduced quality of 
life due to pain and dysfunction. (Osipoff et al., 2020) There re-
mains no curative treatment and therefore management of OLP is 
aimed at reducing mucosal erosions/ulceration and the associated 
painful symptoms. Typically, this is achieved through the reduction 
of local T- cell inflammation and related inflammatory cytokines by 
anti- inflammatory medications, the most commonly used being glu-
cocorticosteroids. Those not responding to glucocorticosteroids 
may benefit from immunosuppressant medications such as topi-
cal tacrolimus or systemic mycophenolate mofetil or azathioprine. 
(Carrozzo et al., 2019).
Systematic reviews and meta- analyses have suggested that 
there remains little robust evidence supporting the use of any of the 
above medications in the treatment of OLP. (Lodi et al., 2020; Yang 
et al., 2016) Toxicity profiles associated with long- term use of the 
above medications can also be significant: ranging from transient lo-
calised mucosal burning to gastrointestinal toxicity, recurrent fungal 
infections, adrenal or bone marrow suppression and increased risk of 
cancer.(Lear et al., 1995; Wee et al., 2012) As affected patients have 
also expressed concerns regarding the self- managed use and the ad-
verse effects of currently available medications. (Ni Riordain et al., 
2011) There is an unmet need to investigate alternative therapeutic 
strategies that may contribute to the long- term management of oral 
lichen planus, ideally with a safer profile.
There have been a number of recent papers that have demon-
strated dysbiosis in the oral microbiome in OLP. (Wang et al., 2020) 
The results produced to date suggest that an alteration in the oral 
bacterial composition may be relevant to the development and pro-
gression of OLP, but the precise role played by the microbiome is 
still unclear. It is possible that targeting dysbiosis may have an im-
pact on disease activity and could be a future therapeutic option 
in OLP.
Here, we present a preliminary clinical study aimed at investi-
gating the potential benefit of probiotics as a novel strategy in the 
treatment of oral lichen planus. Probiotics are food products de-
fined as a live microorganism that confers a health benefit to the 
host. They have been used in a range of medical conditions espe-
cially of the gastrointestinal tract including antibiotic- associated 
diarrhoea, irritable bowel syndrome, ulcerative colitis and pou-
chitis, with the aim of improving intestinal microbial balance, 
enhancing gut barrier function and reducing local and systemic 
inflammation. (Wilkins & Sequoia, 2017) In vitro and animal stud-
ies have suggested that probiotics can induce a reduction in pro- 
inflammatory cytokines. (Plaza- Diaz et al., 2014; Plaza- Diaz et al., 
2017) Clinical studies have indicated possible clinical benefits in 
individuals with inflammatory gastrointestinal disease, although 
robust and conclusive evidence are still lacking. (Iheozor- Ejiofor 
et al., 2020; Kaur et al., 2020) A few small and uncontrolled studies 
have preliminarily assessed the potential beneficial effects of pro-
biotics upon inflammatory diseases of the oral mucosa, although 
evidence remains weak, it has been suggested that the use of 
probiotics in individuals with oral ulceration of Behcet's disease, 
recurrent aphthous stomatitis and chemotherapy- related oral mu-
cositis may lead to clinical benefits including reduced number of 
ulcers, subjective reduction in oral discomfort and reduced sever-
ity of oral mucositis. (Jiang et al., 2019; Rapoport & Levine, 1965; 
Tasli et al., 2006) To the best of our knowledge, there are two pub-
lished studies investigating the use of probiotics as a treatment 
for OLP. (Keller & Kragelund, 2018; Li et al., 2020) The study by 
Keller and Kragelund in 2018, which looked at recurrent oral can-
didiasis in OLP, reported that the administration of the probiotic 
stain Lactobacilli reuteri to symptomatic patients did not reduce 
recurrent oral candidiasis or Candida count/carriage compared 
with placebo. (Keller & Kragelund, 2018) They did however state 
that across the entire study, the placebo group reported a higher 
visual analogue scale (VAS) pain score. In a more recent study by 
Li et al in 2020, it was shown that topical application of the pro-
biotic Streptococcus salivarius K12 produced no adverse reaction 
in symptomatic OLP patients, but produced no significant clini-
cal benefit (Li et al., 2020). The potential of probiotics as a treat-
ment for OLP is still unclear and in need of further investigation. 
Therefore, before embarking on a large multicentre study, we pro-
pose that robustly designed preliminary work is needed in order 
to (a) demonstrate that some beneficial effect can be reasonably 
expected, (b) explore the potential mechanisms of action of the 
study intervention and (c) assess whether such a study would be 
feasible and acceptable to patients.
CABRIO (The clinical and biological effects of the use of probi-
otic in patients with oral lichen planus) was designed as a double- 
blind, randomised placebo- controlled proof of concept pilot trial 
of the probiotic VSL#3 in individuals with symptomatic oral lichen 
planus. The aims of the study included (a) gathering preliminary 
information on clinical benefits including perceived pain [primary 
outcome], disease- specific quality of life (QoL) and disease activ-
ity [secondary outcomes], (b) assessing safety and tolerability of 
the study intervention and participants’ compliance to protocol 
and attrition [secondary outcomes] and (c) measuring the changes 
in pro- inflammatory cytokine levels and oral microbial composition 
as a measure of the underlying mechanisms of action of probiotics 
[mechanistic outcome].
The present report follows the CONSORT 2010 guideline exten-
sion to randomised pilot and feasibility trials. (Eldrige et al., 2016).
2  |  METHODS
2.1  |  Trial Design
CABRIO is a proof of concept parallel group randomised placebo- 
controlled (1:1) pilot trial of probiotics in the treatment of oral li-
chen planus, with embedded feasibility and mechanistic outcomes. 
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The study received favourable ethical opinion by NHS Health 
Research Authority and London– Queen Square NHS Research 
Ethics Committee (protocol 16/0622, IRAS ID 22017). This study 
was registered on ClinicalTrials.gov (NCT03052179) and NIHR 
Portfolio (CPMS ID: 34016). CABRIO is an investigator- led study 
sponsored by University College London (17/LO/0475) with funding 
support from the Industry (award number 174235 from PT. Ferring 
Co. Ltd). Additional infrastructure and service support funding were 
provided by the NIHR UCLH Biomedical Research Centre and NIHR 
Clinical Research Network. Funders had no role in study design or 
data analysis. With the exception of the additional measurement of 
interferon- gamma levels in the saliva, no amendments were made to 
the protocol after the study commenced.
2.2  |  Setting, data and sample collection
Potential participants were identified through the oral medicine outpa-
tient clinics at the Eastman Dental Hospital, University College London 
Hospital Foundation Trust between August 2017 and July 2018. 
Medical notes of attending patients were reviewed against the entry 
criteria, to identify potentially eligible individuals who were subse-
quently approached by the attending clinician and provided with verbal 
and written information on the study. Those who expressed interest in 
participating were invited to consent and attend a screening study visit 
for eligibility checking. Those meeting all the inclusion criteria and none 
of the exclusion criteria were offered recruitment into the study.
Study measurements and participant demographics were col-
lected using a predefined case report form. Saliva and blood sam-
ples were collected at three time points including study visit 1 
(baseline), study visit 3 (after 30 +/- 5 days) and study visit 4 (after 
60 +/- 5 days). Saliva samples were collected in sterile tubes con-
taining saliva preservative buffer (50 mM Tris, pH 8.0, 50 mM EDTA, 
50 mM sucrose, 100 mM NaCl, 1% SDS) by the method of Quinque 
et al (Quinque et al., 2006) and stored at −80℃ until analysed. 
Briefly, volunteers were asked to sit in a dental chair in an upright 
position for two– three minutes, before being asked to spit in to a 
sterile tube containing 2 ml saliva preservative buffer for up to 5 min 
or until the saliva reached 5 ml. Peripheral venous blood samples 
were collected into K2E (EDTA) BD vacutainer® (Becton Dickinson), 
centrifuged at 300 g for 20 mins at 4℃ and the related serum was 
collected and stored at −80℃ until analysed.
2.3  |  Participant inclusion criteria
Inclusion criteria were: (a) biopsy- proven diagnosis of OLP as per 
WHO 1978 histological criteria (Rad et al., 2009) with no evidence of 
oral epithelial dysplasia or malignancy, (b) presence of painful intra- 
oral symptoms associated to OLP at the time of recruitment/start of 
the intervention, with minimum severity of pain being ≥3 on a 0– 10 
numeric pain rating scale, (c) age >18 years and willing to partici-
pate in the study, (4) receiving no therapy or receiving best standard 
topical therapy (defined as self- managed use of topical analgesics, 
corticosteroids or immunosuppressants) at the time of recruitment.
2.4  |  Participant exclusion criteria
Exclusion criteria were: (a) The use of systemic antibiotics, retinoid, 
corticosteroid or immunosuppressant agents within four weeks 
prior to enrolment in the study, (b) pregnancy or receiving IVF treat-
ment, (c) known history of systemic disorders affecting the immune 
system, (d) active cancer or cancer in remission undergoing main-
tenance with chemotherapy or immunomodulatory agents, (e) evi-
dence of oral epithelial dysplasia or oral malignancy on biopsy.
2.5  |  Intervention and study protocol
The investigational study products included active multi- strain 
probiotic and placebo, which were packaged by the manufacturer 
in identical single- use sachets, all of the same size and colour. The 
active study product was a commercially available multi- strain 
probiotic brand named VSL#3 (VSL#3- ACTIVE Batch 703093 Exp. 
date 04/2019, provided by Actial Farmaceutica srl, Italy) contain-
ing >450 billion live bacteria per sachets (4.4 g). The strains con-
tained within VSL#3 were listed as Lactobacillus acidophilus (BA05), 
Lactobacillus delbrueckii subsp. Bulgaricus (BD08) (reclassified as 
lactobacillus helveticus), Lactobacillus paracasei (BP07), Lactobacillus 
plantarum (BP06), Bifidobacterium longum (BL03), Bifidobacterium in-
fantis (BI04) (BL03 and BI04 reclassified as B. animalis subsp.lactis), 
Bifidobacterium breve (BB02) and Streptococcus thermophilus (BT01). 
(Mora et al., 2019) The active products also contained maltose, corn 
starch and anti- cracking agent silicon dioxide while the placebo 
product consisted of maltose, corn starch and anti- cracking agent 
silicon dioxide but no probiotic. The presence of the same flavouring 
agents in both active and placebo products ensured no difference 
in flavour.
Participants in both the placebo and the active arm were in-
structed to take the study product at home, dissolve the contents of 
two sachets into cold water or fruit juice in the morning with break-
fast and two in the evening with dinner and swallow it (four sachets 
per day in total), every day for 30 days. Participants were provided 
with a home diary to be completed twice a day with information re-
garding the time of the day when the study products were used and 
were also asked to return the study products that had not been used 
at the subsequent study visit.
Participants were allowed to use self- managed standard of care 
topical therapy during the study where needed, including topical an-
algesics, corticosteroids or immunosuppressants. Participants, who 
after commencing the trial, were prescribed systemic antibiotics 
because of an infection at any body site and those who were pre-
scribed systemic corticosteroids or immunosuppressants because 
of unsatisfactory response to topical therapy were excluded from 
analysis. All adverse events and serious adverse events (expected 
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and unexpected) were collected and reported as per good clinical 
practice, with the exception of those events that were considered 
unrelated to the intervention.
2.6  |  Primary outcome and primary 
outcome measure
The primary outcome was the change in intra- oral painful symptoms 
after 30 days of VSL#3 probiotic use with respect to baseline, as 
measured by pain numeric rating scale (pNRS). The pNRS was de-
signed as a horizontal line with the numbers on a scale from 0, which 
represents no pain, to 10, representing the worst possible pain. This 
scale has been previously validated for measurement of the intensity 
of painful symptoms in OLP. (Escudier et al., 2007) For each study 
visit, participants were asked to mark the number on the pNRS ac-
cording to their subjective experience over the previous two weeks 
including the day of the study visit.
2.7  |  Secondary outcomes and secondary 
outcome measures
The secondary outcomes included change in intra- oral painful 
symptoms at 15 days and the end of the study defined as the pNRS 
score at final review visit (day 60 +/- 5 days, 30 days after stop-
ping the intervention) compared with baseline, and the change in 
intra- oral painful symptoms over time, as measured by assessing 
pNRS scores at baseline, 15- day, 30- day and 60- day review vis-
its in each randomised group. Secondary outcomes also included 
the change from baseline in Oral Disease Severity Score (ODSS) 
(Escudier et al., 2007) and quality of life (QoL) as determined by 
the chronic oral mucosal disease questionnaire (Ni Riordain et al., 
2016; Ni Riordain & McCreary, 2011) at 15, 30 and 60 days, as well 
as over time.
In addition, a number of feasibility outcomes were considered 
including safety and tolerability of the intervention, and attrition/
compliance with protocol, which were assessed by recording ad-
verse side effects, completion of participant home diary, the number 
of returned unused study products, non- attendance to study visits, 
related missing measurements and withdrawals.
With respect to the mechanistic outcomes, we assessed the 
change from baseline in salivary and serum levels of the pro- 
inflammatory chemokine CXCL10 and IFN- γ at day 30 and day 60. 
IFN- γ and CXCL10 have previously been shown to be upregulated 
in OLP mucosal tissue, saliva and serum and may have an important 
role in regulating the inflammatory pathogenesis of OLP. (Abdel- 
Haq et al., 2014; Akpinar Kara, 2017; Deng et al., 2020; Di Lernia, 
2016; Marshall et al., 2017; Nibali et al., 2012; Sun et al., 2005) An 
analysis of the changes in oral microbial composition from base-
line and day 60 was conducted using 16S rRNA sequencing (for 
full details of the methodology see Supplementary Materials and 
Methods).
2.8  |  Post- hoc exploratory outcome
Changes in topical corticosteroid usage over the duration of the trial 
were assessed in the two study arms as a surrogate of potential ben-
eficial effects upon painful symptoms and the perceived need to use 
corticosteroid treatment.
2.9  |  Sample size
A pragmatic sample size of 30 participants was chosen for this proof- 
of- concept pilot study. Recruitment of thirty participants was con-
sidered realistically achievable within the timeframe of this trial and 
the capacity of the oral medicine clinics at UCLH EDH, as well as 
adequate for the objectives of this preliminary study. (Julious, 2005).
2.10  |  Randomisation, allocation concealment, 
implementation and blinding
A centralised computer- generated randomisation list was used to 
allocate participants to the active probiotics or placebo arm. An in-
dependent third- party statistician provided the electronic randomi-
sation list, which included the identifiers to the study subjects and 
the treatment allocation, to the drug manufacturer who labelled the 
probiotics and placebo packages accordingly. All other aspects of 
the packaging were identical to ensure blinding. The randomisa-
tion list was blocked using varying block sizes and 1:1 allocation to 
the treatment and control groups. The emergency unblinding code 
was held in a password- protected electronic format on a secure 
password- protected drive by a member of the research team (SRP) 
who was not involved in participant recruitment and management, 
and was not viewable by other investigators until the database was 
unlocked. Paper copies of the randomisation key in closed enve-
lopes, one for each participant, were also held by the same indi-
vidual (SRP) and stored in a locked cabinet within a locked room with 
swipe card access system, to be accessed only in case of emergency 
unblinding.
Participants were recruited and allocated a study identifier and 
corresponding package of study treatment by research nurses. All 
study investigators recruiting or caring for trial participants did not 
have access to the randomisation list and were therefore blinded to 
the interventions. Packaging and labelling of active probiotics and 
placebo, as well as their administration, were identical between 
groups therefore ensuring participant blinding.
2.11  |  Statistical analysis
Participant baseline data including demographics and clinical char-
acteristics was summarised by randomised group. For the primary 
outcome (change in pain after 30 days), we compared the aver-
age change in pNRS score at 30 days between randomised groups 
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making adjustment for baseline using a linear regression model (anal-
ysis of covariance) (Douglas, 1990; Gardner & Altman, 1986; Vickers 
& Altman, 2001).
With respect to the secondary outcomes, we used a similar 
model to compare the mean change in pNRS score at 15 and 60 days 
between randomised groups adjusting for baseline and used graphs 
to examine the changes in mean pNRS score over time in each ran-
domised group (including scores at baseline, 15- day, 30- day and 60- 
day time points).
Regression models were also used to compare the average 
changes in OLP disease activity score ODSS and QoL score at 15, 
30 and 60 days adjusted for baseline and graphically examined the 
changes in mean ODSS and QoL score over time in each randomised 
group.
The feasibility outcomes were reported narratively and describ-
ing the occurrences of adverse events (safety and tolerability) and 
the withdrawal rate (attrition) summarised by randomised group 
using counts and proportions. We also reported descriptively on the 
changes in the use of corticosteroid therapy during the trial and the 
compliance to protocol by summarising the information obtained 
from participant diaries.
We compared the changes in mean levels of serum and salivary 
cytokines in each randomised group at 30- day and 60- day adjusted 
for baseline. For metagenomics analysis comparing salivary mi-
crobiome in individuals at baseline and day 60 as well as between 
groups, we used non- parametric statistical tests on the Bray– Curtis 
dissimilarity distances (full details can be found in Supplementary 
Materials). All analyses described in the main manuscript were as per 
protocol. For transparency and completeness, the intention to treat 
(ITT) analysis can be found in Supplementary Figure S1.
Statistical analysis was conducted using STATA (https://www.
stata.com/) and significance set at p < 0.05. No correction for multi-
ple testing was performed.
3  |  RESULTS
3.1  |  Participant flow, demographics and baseline 
measurements
We pre- screened against study criteria the medical notes of 1,748 
consecutive OLP individuals attending the oral medicine clinic of 
UCLH Eastman Dental Hospital from July 2017 to June 2018. Of 
them, 1,393 were excluded (reasons provided in the CONSORT 
flow diagram) (Figure 1), and 355 were considered potentially eligi-
ble and approached in the clinic with information about the trial. Of 
these, 267 declined participation (age range 59 ± 11.7, due in part 
to a lack of availability to attend the required four study visits over 
a 60 day period. Thirty- five expressed an interest in the study and 
were consented and invited to attend a first screening visit for final 
eligibility checking. Of the 35 individuals who attended the study 
visit for eligibility assessment, 30 met all the inclusion and none of 
the exclusion criteria and were randomised into the placebo (n = 15) 
or probiotic (n = 15) arm. The first and last participants were ran-
domised in August 2017 and July 2018 respectively. One participant 
in the placebo group and two in the VSL#3 group were withdrawn 
from the study intervention (on day 13, 11 and 14, respectively), 
as they required a course of antibiotic for dental (1 individual) and 
urinary tract infections (2 individuals). These three individuals were 
withdrawn from the treatment, but were required to attend the re-
maining study visits. Therefore, fourteen participants in the placebo 
group and thirteen participants in the probiotic group completed 
the trial intervention as per protocol and were included in the anal-
ysis. Demographics and baseline clinical measurements of all par-
ticipants who completed the trial are summarised in Tables 1 and 
2 respectively. The randomisation procedure resulted in no notable 
differences in demographics or clinical measurements between the 
placebo and VSL#3 groups at day 0 (baseline).
3.2  |  Primary outcome (change in pNRS score at 
30 days)
Both VSL#3 and placebo groups showed similar reductions in mean 
pNRS scores at day 30 compared with baseline, with no evidence 
of a statistically significant difference between randomised groups 
(p = 0.749, adjusted difference in mean pain score was 0.48 with 
95% CI −1.46 to 1.12) (Figure 2A).
3.3  |  Secondary outcomes
With respect to change in pNRS at 15 days with p = 0.315, adjusted 
difference in mean pain score was 0.69 with 95% CI −2.34 to 0.81 
and 60 days (30 days after the end of the intervention) demon-
strated no evidence of a difference in means between VSL#3 and 
placebo groups (p = 0.412 adjusted difference in mean pain score 
was 0.46 with 95% CI, −2.66 to 1.09) (Figure 2A). Furthermore, the 
mean changes in pNRS over time followed a similar trajectory in both 
groups, with a decline in mean pain score from baseline at days 15 
and 30, followed by an elevation at day 60, with no statistically sig-
nificant difference between the two groups at any of the time points 
(Figure 2A).
Analysis of the change in ODSS mean score showed no statis-
tically significant differences between groups at 15 (p = 0.723 ad-
justed difference in ODSS was 0.75 with 95% CI −5.9 to 3.46), 30 
(p = .0.914 adjusted difference in ODSS was 0.69 with 95% CI, −4.82 
to 5.32) and 60 days (p = 0.861 adjusted difference in mean ODSS 
was 0.94 with 95% CI, −4.94 to 5.86) (Figure 2B). There was no dif-
ference in the ODSS mean scores between the VSL#3 and placebo 
groups over time (Figure 2B).
Analysis of the changes in QoL mean scores showed no statis-
tically significant differences between groups at 15 (p = 0.192 ad-
justed difference in QoL was 0.94 with 95% CI −2.2 to 11.04), 30 
(p = 0.518 adjusted difference in QoL was 1.12 with 95% CI, −5.78 
to 10) and 60 days (p = 0.96 adjusted difference in QoL was 1.03 
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with 95% CI, −9.25 to 9.4) (Figure 2C). Analysis of the QoL mean 
score changes over time showed no statistically significant differ-
ence between groups at days 15 and 30 (p = 0.192 and p = 0.518, 
respectively).
3.4  |  Feasibility Outcomes
There was very good compliance with the study protocol, the total 
attrition being 10% (3 out of 30 participants were withdrawn). All 
F I G U R E  1  CONSORT (consolidated 
standards of reporting trials) flow diagram 
of CABRIO Study. AB, Antibiotic; CS, 
Corticosteroid
Baseline Variable









Age (Mean ± SD) 56.1 ± 11.8 55.1 ± 11.5 59.3 ± 8.3 59.5 ± 8.9
Gender (%)
Female 12 (80) 11 (78.57) 12 (80) 10 (76.92)
Smoke (% Yes) 2 (13.33) 1 (7.14) 0 (0) 0 (0)
Alcohol in unit (%, weekly)
0– 5 13 (86.67) 12 (85.7) 11 (73.3) 10 (76.92)
6– 10 1 (6.67) 1 (7.14) 4 (26.67) 3 (23.08)
11– 15 1 (6.67) 1 (7.14) 0 (0) 0 (0)
Topical (% Yes) 11 (73.33) 10 (71.43) 12 (80) 11 (84.62)
Race (%)
White 8 (56.67) 7 (50) 9 (60) 7 (53.85)
Asian 7 (46.67) 7 (50) 6 (40) 6 (46.15)
TA B L E  1  Baseline demographic 
characteristics of CABRIO participants
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participants completed all study visits. Analysis of the partici-
pant home diary and the number of returned unused study prod-
ucts showed high compliance in both groups: 100%, 90– 99% and 
80– 89% compliance were seen in four, nine and one participants of 
the placebo group and six, five and two participants of the active 
group respectively (Table 3).
With respect to the tolerability and safety of the intervention, 
the patients in the VSL#3 group showed the same proportion of ad-
verse events as the placebo group (Table 3). Bloating, which is listed 
by the manufacture as an expected side effect of consuming VSL#3, 
was the most frequently reported adverse event in both the VSL#3 
(n = 3) and placebo (n = 3) groups.
3.5  |  Mechanistic outcomes
Analysis of changes in salivary CXCL10 levels for 30 and 60 days 
showed a weak (but not statistically significant) trend towards a re-
duction in the VSL#3 group after adjustment for baseline: difference 
in means (placebo- VSL#3) 0.15 with 95% CI −1.52 to 4, p = 0.143, and 
0.14 with 95% CI −3.58 to 2.37 p = 0.614, respectively (Figure 3A). 
Changes in serum CXCL10 levels at 30 and 60 days also showed no 
statistically significant difference after adjustment for baseline: dif-
ference in means (placebo- VSL#3) 0.31 with 95% CI −0.86 to 5.67, 
p = 0.894, and 1.15 with 95% CI −2.5 to 5.85, p = 0.77, respectively 
(Figure 3B).
Analysis of the change in salivary IFN- γ revealed no significant 
alteration between the VSL#3 group compared with the placebo 
group at day 30 (p = 0.082, difference adjusted for baseline was 1.68 
with 95% CI −0.66 to 0.2) (Figure 3C). The change between groups 
at day 60 was also not significant (p = 0.587, difference adjusted 
for baseline was 1.26 with 95% CI, −0.2 to 0.17). IFN- γ levels in the 
serum were too low to measure and therefore not analysed.
The analysis showed that the consumption of VSL#3 or pla-
cebo had no significant influence on saliva microbiome variation 
(Table 4). Although there were notable changes in the saliva micro-
biomes between day 0 and day 60, similar shifts were seen in both 
the placebo and the VSL#3 groups and there was no statistical dif-
ference between the two groups at either timepoint (Figure 4 and 
Table 4b). Overall, the 16S rRNA analysis showed that VSL#3 did 
not significantly impact on the composition of the salivary micro-
biome in OLP patients 30 days after consumption of the probiotic 
ceased.
3.6  |  Topical corticosteroid usage
This post- hoc exploratory analysis showed that the total number of 
participants in the active and placebo group who used self- managed 
topical corticosteroids at any time point during the trial was 11 
(out of 13) and 10 (out of 14) respectively (Table 1). The number of 
patients using topical corticosteroid, as well as the number of ap-
plications per day, dropped during the study in both the active and 
placebo groups (Figure 5). The difference between groups was not 
found to be statistically significant for the number of participants 
taking topical corticosteroids at day 30 or 60 (p = 0.06 and 0.071 




Baseline Day 0 variables (Mean ± SD)
Placebo (n = 14) VSL#3 (n = 13) p value
pNRS 5.39 ± 2.11 5.27 ± 1.61 0.867
ODSS 26.6 ± 6.25 29.8 ± 10 0.342
QoL 52.43 ± 20.12 59.15 ± 15.6 0.642
Note: Students T- test.
F I G U R E  2  Alteration in clinical scores compared with baseline 
measurements over the trial period. Mean change in (a) pNRS, 
(b) ODSS and (c) QoL scores. p- values are from a comparison of 
randomised groups adjusting for the baseline score. Placebo group 
n = 14, VSL#3 group n = 13, Mean +95% CI
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respectively, Fisher's exact test, two- tailed) or in regard to the alter-
ation in number of applications per day (p = 0.347 Student T- Test).
4  |  DISCUSSION
CABRIO to our best knowledge was the first trial investigating the 
potential use of a multi- species probiotic supplement in the treatment 
of OLP. The protocol design also contained an embedded mechanistic 
study aimed at understanding the potential mode of action.
Our findings show that the highly concentrated probiotic VSL#3 
was safe and well tolerated by patients with OLP. We observed no 
convincing evidence of a notable reduction in pain, disease activity 
or QoL at day 30 and 60 endpoints of the study in the active group 
with respect to placebo. However, the analysis of changes over time, 
which is particularly relevant for longitudinal studies of interven-
tions for chronic diseases, (Senn et al., 2000) showed a reduction in 
mean QoL scores in the active group compared with placebo at days 
15 (p = 0.192) and 30 (p = 0.518), although statistical significance 
was not reached. As an indirect surrogate signal indicating a poten-
tial effect of VSL#3 consumption, we observed a reduction in the 
number of participants in the active group taking topical corticoste-
roid at the 30- day endpoint, this was not significant when compared 
with the placebo group (p = 0.06).
TA B L E  3  Associated/non- associated adverse events and compliance for CABRIO participants
GROUP Patient Number
% Compliance
(100% = 120 sachets)
Adverse Event
Associated Non- associated
PLACEBO 1 100 - Shoulder pain
2 - Withdrawn from study due to antibiotic use (UTI)
3 >100 - - 
4 100 - - 
5 100 - - 
6 >100 Bloating Cold
7 100 - Cold
8 >100 - Nausea
9 100 Bloating/Nausea - 
10 95 Bloating Sinusitis
11 81 - Flatulence
12 98 - - 
13 100 - - 
14 >100 - Swollen gland
15 93 - Haemorrhoid operation
VSL#3 1 93 Bloating/vomit Headache
2 >100 - CS injection
3 81 - Car accident
4 >100 - Stomach pain/cramp
5 >100 - - 
6 96 Bloating Migraine
7 86 - - 
8 - Withdrawn from study due to antibiotic use 
(Dental)
9 96 - - 
10 >100 - Migraine
11 96 - - 
12 >100 - Stomach cramp, dental
13 91 Bloating - 
14 - Withdrawn from study due to antibiotic use (UTI)
15 >100% - - 
Note: >100% compliance achieved when participant consumed more than the required 120 sachets, which usually occurred when participants 
attended visit 3 between days 31 and 35.
Abbreviations: CS, corticosteroid; UTI, urinary tract infection.
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There have been two previous published studies on the use of 
single species probiotics and OLP, which have reported similar re-
sults to our findings. Li et al, carried out a pilot randomised controlled 
study to evaluate Streptococcus salivarius K12 in the treatment of 
patients with symptomatic OLP. The participants were provided 
with either 0.1% triamcinolone acetonide dental paste or S. salivar-
ius K12 lozenges 1 tablet twice daily (~1 billion CFU/unit of S. sali-
varius). They reported no significant difference in the VAS between 
the two groups after 4 weeks, in agreement with our findings. (Li 
et al., 2020) Keller et al also performed a double- blind randomised, 
placebo- controlled intervention study investigating the potential 
effects of probiotics in recurrent oral candidiasis in patients with 
OLP. (Keller and Kragelund, 2018) Lozenges containing Lactobacillus 
reuteri were consumed for 16 weeks and clinical parameters includ-
ing VAS, severity score, Candida numbers, plaque and gingival index 
were reported. No difference in recurrent oral candidiasis, Candida 
count over time was seen with probiotic treatment. Gingival index 
decreased in the probiotic group and increased in the placebo group 
and over the entire study the placebo group produced a higher VAS 
pain score. The disparity in VAS results between the three studies 
could be due to a number of factors, such as mode of delivery, pa-
tient populations, presence of oral candidiasis, probiotic species 
used, dosage levels and duration of consumption. Further studies 
are needed to determine the potential of probiotics in the treatment 
of OLP and associated conditions.
With respect to the mechanistic outcomes, the analysis of 
changes in salivary levels of CXCL10 showed no significant reduc-
tion in the active group. The changes in salivary levels of IFN- γ be-
tween groups showed a reduction in the active group at 30 days 
(p = 0.08), which was not statistically significant. It is important to 
mention we did not measure salivary flow rate in the participants 
during the study. Salivary flow rate is known to be abnormal in OLP 
and this may have impacted on our findings associated with saliva 
cytokine levels and microbiome composition. (Mansourian et al., 
2018) Future studies would benefit from recording the salivary flow 
rates of participants during the trial period.
There are a number of factors that may explain the lack of more 
robust results and statistical significance of our findings. CABRIO 
was designed as a proof- of- concept trial with a pragmatic sample 
size and as such it was not specifically powered to detect statis-
tically significant meaningful changes related to clinical efficacy. 
There were also a number of measurements and information that 
was not included as part of the proof- of- concept study that may 
have influenced the findings, such as saliva flow rate, the presence 
of secondary oral candidiasis both of which are known features of 
OLP. It is possible that both saliva flow rate and candidiasis could 
impact on disease activity, cytokine levels and microbiome com-
position. It is also possible that probiotic consumption could alter 
the fungal populations within the saliva as well as saliva flow rate. 
Follow on studies would benefit from including these two addi-
tional parameters. The mode of administration of the product was 
not standardised for participants and different consumption re-
gimes might have contributed to variability in results. Participants 
were requested to either pour the sachet content on their food, 
drink or to eat it directly. Although specific instructions were pro-
vided to each participant requesting, they do not add the product 
to carbonated soda, hot food or hot drink, no further instructions 
were provided. It is therefore possible that some variation in mode 
of consumption exists and this could impact on the findings. Future 
studies would benefit from a standardised mode of consumption 
for all participants.
F I G U R E  3  Alteration in pro- inflammatory cytokine levels 
compared with baseline measurements over the trial period. 
Change in (a) salivary CXCL10 levels, (b) serum CXCL10 levels, (c) 
salivary IFN- γ levels. Placebo group n = 14, VSL#3 group n = 13
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TA B L E  4  Comparison of saliva microbiome composition (A) between baseline and day 60 for VSL#3 and placebo groups, (B) between 
VSL#3 and placebo groups at baseline and day 60, using three non- parametric statistical tests. PERMANOVA, ANOSIM and MRPP tests on 
Bray– Curtis distances. All three tests showed that the consumption of placebo or VSL#3 had no significant influence on saliva microbiome 
variation on days 0 and 60 of the study
A.
Variable
Non- parametric statistical test (p- value) Day 0 and Day 60 saliva microbiome composition
PERMANOVA ANOSIM MRPP
Placebo 0.862 0.920 0.864
VSL#3 0.946 0.984 0.994
B.
Variable
Non- parametric statistical test (p- value) saliva microbiome composition between VSL#3 and placebo 
groups
PERMANOVA ANOSIM MRPP
Day 0 (Baseline) 0.952 0.847 0.941
Day 60 0.801 0.683 0.610
Significance reached at p < 0.05.
F I G U R E  4  An analysis of salivary microbiome variation between samples taken on Day 0 and Day 60. (a) Difference in relative abundance 
of the top 25 genera between day 0 and day 60. (b) Multidimensional scaling/principal coordinates analysis (MDS/PCoA) was carried 
out separately on saliva samples taken from placebo- prescribed (•) and VSL#3- prescribed (∆) individuals. Paired samples from the same 
individual are connected by solid lines. Placebo group n = 14, VSL#3 group n = 13
F I G U R E  5  Change in corticosteroid 
usage. (a) Change in number of 
participants applying daily topical 
corticosteroid. (b) Reduction in number of 
topical corticosteroid applications per day 
per individual at day 30 of the clinical trial. 
Analysis by Fisher's exact test. Placebo 
group n = 14, VSL#3 group n = 13
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The provision of study intervention was designed as potentially 
adjuvant, as participants were allowed to use their standard of care 
topical corticosteroid therapy during the trial as needed. This may 
have masked or reduced the magnitude of the intervention effects 
upon participants’ symptoms and disease activity. Interestingly, we 
observed a trend, which did not attain statistical significance, to-
wards a reduction in the number of participants in the active group 
self- administering topical corticosteroid during the trial (p = 0.06), 
which suggests that individuals taking the active probiotic may have 
perceived a reduced need to use their standard therapy as they pro-
gressed in the trial. It is possible that this was a consequence of some 
degree of reduction in disease activity and painful symptoms, albeit 
with a magnitude that was too small to be captured by changes in 
the pNRS or ODSS scores, but meaningful enough to patients so to 
determine a subjective reduction in the use of standard topical cor-
ticosteroid therapy. We did not record the volume of topical corti-
costeroid applied at each application and this could differ between 
subjects and have an influence on the findings. Larger and longer 
studies will be needed to verify these statements.
Interestingly, we did not observe notable changes in the sali-
vary microbiome on day 60 as compared with baseline or between 
groups, therefore VSL#3 does not seem capable of changing the 
composition of the salivary microbiome when measured a month 
after consumption was stopped. The potential biological effects of 
VSL#3 on CXCL10 and IFN- γlevels, and clinically upon QoL scores 
and the perceived need of using topical corticosteroids may re-
quire continuous consumption of the product, as we observed no 
improvement in cytokine levels or clinical scores between days 30 
and 60. The observed reduction in QoL scores and in saliva cytokine 
levels were recorded on days 15 and 30, which coincided with the 
consumption of VSL#3. Interestingly, the control group responded in 
a similar manner, which suggests either a placebo effect or a general 
response to the application of corticosteroids that all participants 
were permitted to self- administer during the study. The perceivable 
placebo effect in the participants will need to be considered when 
designing future clinical studies in OLP. The inclusion of an untreated 
control group in any future study would allow the true placebo ef-
fect in this population to be determined. A longer and larger study 
is needed to determine if continued VSL#3 consumption provides 
additional benefits to symptomatic OLP patients.
5  |  CONCLUSIONS
The present proof- of- concept study does not provide sufficient evi-
dence to support the notion that VSL#3 has any biological or clinical 
effects in individuals with painful lesions of OLP. It remains unclear 
whether the lack of more encouraging and robust results is due to a 
genuine lack of beneficial effects in this patient population or other 
factors unrelated to investigational product. The latter include the 
proof- of- concept nature of the trial, which was not designed or pow-
ered to demonstrate efficacy, and the use of VSL#3 as an adjuvant 
treatment along with standard of care topical corticosteroid therapy. 
The preliminary results of CABRIO suggest that further research in 
this field is warranted and provides useful information with respect 
to aspects of the design of a subsequent phase II study.
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